Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal
Business Wire•09/11/2026•23:47 ET
0
Key Highlights
- ➤Federal Circuit heard oral arguments on Acadia’s NUPLAZID formulation patent appeal
- ➤Decision expected in first half of 2027, with no set ruling timeline
- ➤Patent upheld would protect NUPLAZID 34 mg capsules through February 2038
- ➤Patent overturned would leave protection through October 2030
- ➤NUPLAZID negotiated price expected to take effect in 2029
Expert Statements
Catherine Owen Adams, Chief Executive Officer of Acadia Pharmaceuticals
“We continue to believe in the strength of our position on the NUPLAZID formulation patent, on which the Federal Circuit heard oral arguments today”
Catherine Owen Adams, Chief Executive Officer of Acadia Pharmaceuticals
“Acadia believes the district court’s decision is supported by the facts established at trial and by applicable law.”
Catherine Owen Adams, Chief Executive Officer of Acadia Pharmaceuticals
“The trial court decided key issues of fact after hearing detailed testimony from experts. Such factual findings should receive deference from the appeals court.”
Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today reported that oral arguments were held before the U.S. Court of Appeals for the Federal Circuit in the appeal of the U.S. District Court for the District of Delaware’s May 2025 decision upholding Acadia’s U.S. Patent No. 11,452,721 (the ‘721 patent), which covers the NUPLAZID® (pimavanserin) 34 mg capsule formulation.
Get started
Create a free account to read the full story.